MEDP — Medpace Holdings, Inc. stock price, charts and financials

NASDAQ·Healthcare·Medical - Diagnostics & Research·USA

Latest market price

612.33

-2.85-0.46%

Overview Short InterestFilings

MEDPQT74Medpace Holdings, Inc.·NASDAQ

Overview Short InterestFilings

612.33-0.46%

Loading chart...

Signal & projected range

Insider open-market saleHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

RVTY-2.24%$143.45 CRL-1.28%$278.06 ICLR-3.28%$164.11 GH-2.03%$179.38 LH-0.63%$320.71 DGX-0.40%$246.45 MTD-1.28%$1392.32 WAT-1.88%$421.63

Snapshot

Index	-	P/E	35.21	EPS (ttm)	17.39	Insider Own	47.47%	Shs Outstand	27.91M	Perf Week	4.22%

Market Cap	17.09B	Forward P/E	31.65	EPS next Y	19.35	Insider Trans	-1.33%	Shs Float	22.50M	Perf Month	0.67%

Enterprise Value	16.71B	PEG	1.36	EPS next Q	4.45	Inst Own	-	Short Float	7.43%	Perf Quarter	33.06%

Income	485.39M	P/S	6.14	EPS this Y	3.12%	Inst Trans	-	Short Ratio	5.50	Perf Half Y	32.85%

Sales	2.78B	P/B	39.95	EPS next Y	9.92%	ROA	23.89%	Short Interest	1.67M	Perf YTD	9.02%

Book/sh	-	P/C	23.03	EPS next 5Y	10.62%	ROE	110.15%	52W High	677.88 -9.67%	Perf Year	23.00%

Cash/sh	-	P/FCF	23.30	EPS past 3/5Y	28.04% 31.81%	ROIC	77.00%	52W Low	373.01 64.16%	Perf 3Y	117.39%

Dividend Est.	-	EV/EBITDA	27.75	Sales past 3/5Y	20.11% 22.26%	Gross Margin	28.76%	Volatility	2.56% 2.49%	Perf 5Y	219.40%

Dividend TTM	-	EV/Sales	6.01	EPS Y/Y TTM	35.15%	Oper. Margin	20.97%	ATR (14)	15.67	Perf 10Y	1937.70%

Dividend Ex-Date	-	Quick Ratio	0.73	Sales Y/Y TTM	31.91%	Profit Margin	17.67%	RSI (14)	58.83	Recom	2.84

Dividend Gr. 3/5Y	-	Current Ratio	0.73	EPS Q/Q	37.10%	SMA20	1.64%	Beta	1.16	Target Price	606.38

Payout	0.00%	Debt/Eq	0.28	Sales Q/Q	17.25%	SMA50	4.71%	Rel Volume	1.77	Prev Close	615.18

Employees	6,500	LT Debt/Eq	0.50	Earnings	Oct 28	SMA200	17.55%	Avg Volume	294.51K	Price	612.33

IPO Date	Aug 11, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	6.84% 2.58%	Net Debt/EBITDA	-0.64	Volume	520,912	Change	-0.46%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-24-26	Reiterated	Robert W. Baird		$547 → $624
Jul-24-26	Reiterated	RBC Capital	Outperform	$484 → $692
Jul-24-26	Reiterated	Mizuho	Outperform	$586 → $665
Jul-24-26	Reiterated	BMO Capital	Market Perform	$400 → $600
Jul-23-26	Reiterated	Barclays	Equal Weight	$450 → $600
Jul-23-26	Reiterated	Leerink Partners	Market Perform	$515 → $620
Jul-23-26	Reiterated	Deutsche Bank	Hold	$480 → $535
Jul-13-26	Reiterated	Mizuho	Outperform	$582 → $586
Jul-08-26	Reiterated	Robert W. Baird		$477 → $547
Jul-08-26	Downgrade	Baird	Outperform → Neutral

Latest News· Times ET

Sep-18-26

Sep-18-2612:02AM

Medpace Holdings, Inc. $MEDP Stock Position Decreased by Integrated Wealth Concepts LLCdefenseworld.net

Sep-15-26

Sep-15-2601:01AM

Medpace Holdings, Inc. $MEDP Stock Position Decreased by Engineers Gate Manager LPdefenseworld.net

12:27AM

Waverly Advisors LLC Trims Stake in Medpace Holdings, Inc. $MEDPdefenseworld.net

Sep-14-26

Sep-14-2603:15PM

Medpace (MEDP) Ascends While Market Falls: Some Facts to Notezacks.com

Sep-11-26

Sep-11-2611:40AM

CON vs. MEDP: Which Stock Is the Better Value Option?Yahoo

Sep-04-26

Sep-04-2608:49AM

Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich?Yahoo

Sep-01-26

Sep-01-2607:01AM

President & CEO Of Medpace Holdings Makes $403K SaleBenzinga

06:46AM

Why Medpace (MEDP) is a Top Growth Stock for the Long-Termzacks.com

Aug-26-26

Aug-26-2611:35PM

American Capital Management Inc. Invests $111.33 Million in Medpace Holdings, Inc. $MEDPdefenseworld.net

09:21AM

Medpace Stock Hovers Near Entry, Offers Second Chance After July Spikeinvestors.com

08:41AM

CON vs. MEDP: Which Stock Should Value Investors Buy Now?zacks.com

07:00AM

If You Invested $1000 In Medpace Holdings Stock 10 Years Ago, You Would Have This Much TodayBenzinga

02:53AM

What Investors Should Know About Medpace CEO Troendle Selling $10 Million in Stockfool.com

Aug-25-26

Aug-25-2611:57PM

Bank of New York Mellon Corp Takes Position in Medpace Holdings, Inc. $MEDPdefenseworld.net

Aug-21-26

Aug-21-2611:49PM

B. Metzler seel. Sohn & Co. AG Invests $4.74 Million in Medpace Holdings, Inc. $MEDPdefenseworld.net

Company

Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	2,782	2,530	2,109	—	—	—	—	—	—
Cost of Goods Sold Incl. D&A	1,982	1,770	1,453	—	—	—	—	—	—
Gross Profit	800	761	656	—	—	—	—	—	—
Selling, General and Administrative Excl. Other	189	198	180	—	—	—	—	—	—
Research and Development	0	0	0	—	—	—	—	—	—
Other Operating Expense	28	28	29	—	—	—	—	—	—
Operating Income	584	535	447	—	—	—	—	—	—
Interest Expense	0	0	0	—	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	16	7	29	—	—	—	—	—	—
Net Income Before Taxes	600	542	476	—	—	—	—	—	—
Income Taxes	108	91	72	—	—	—	—	—	—
Consolidated Net Income	491	451	404	—	—	—	—	—	—
Net Income From Continuing Operations	491	451	404	—	—	—	—	—	—
Net Income	491	451	404	—	—	—	—	—	—
EPS (Recurring)	17.39	15.64	13.06	—	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	17.39	15.64	13.06	—	—	—	—	—	—
EPS (Diluted)	17.07	15.28	12.63	—	—	—	—	—	—
EBITDA	602	571	505	—	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	35.87	36.76	26.30	—	—	—	—	—	—
Price To Sales Ratio	6.16	6.44	4.88	—	—	—	—	—	—
Gross Margin	28.76	30.08	31.10	—	—	—	—	—	—
Operating Margin	20.99	21.15	21.19	—	—	—	—	—	—
Net Margin	17.65	17.83	19.16	—	—	—	—	—	—
Shares Outstanding	28	29	31	—	—	—	—	—	—
Market Capitalization	17,145	16,288	10,299	—	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Troendle August J.	President & CEO	Sep 16 '26	Sale	621.29	8,770	5,448,713	515,153	Sep 17
Troendle August J.	President & CEO	Sep 15 '26	Sale	620.84	15,971	9,915,436	523,923	Sep 17
BURWIG SUSAN E	Exec. VP, Operations	Sep 15 '26	Option Exercise	166.73	3,000	500,190	65,984	Sep 17
Troendle August J.	President & CEO	Aug 27 '26	Sale	620.27	650	403,176	539,894	Aug 31
Kraft Robert O.	Director	Aug 26 '26	Option Exercise	84.36	3,858	325,461	4,813	Aug 28
Kraft Robert O.	Director	Aug 26 '26	Sale	617.81	3,858	2,383,511	955	Aug 28
Troendle August J.	President & CEO	Aug 26 '26	Sale	620.03	4,000	2,480,120	540,544	Aug 27
Troendle August J.	President & CEO	Aug 25 '26	Sale	620.38	673	417,516	544,544	Aug 27
Troendle August J.	President & CEO	Aug 24 '26	Sale	620.23	1,983	1,229,916	545,217	Aug 25
Troendle August J.	President & CEO	Aug 21 '26	Sale	624.45	13,995	8,739,178	547,200	Aug 25
Brady Kevin M.	CFO & Treasurer	Aug 20 '26	Option Exercise	138.87	3,400	472,158	16,230	Aug 24
Brady Kevin M.	CFO & Treasurer	Aug 20 '26	Sale	625.24	3,400	2,125,816	12,830	Aug 24
Troendle August J.	President & CEO	Aug 20 '26	Sale	618.79	27,174	16,814,999	561,195	Aug 21
Carley Brian T	Director	Aug 19 '26	Sale	608.63	5,000	3,043,150	27,825	Aug 21
DAVENPORT FRED B JR	Director	Aug 19 '26	Option Exercise	116.08	7,583	880,263	11,081	Aug 21

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.